WHO ICTRP trial
W10TR-PRO1
JPRN-jRCTs061180084 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs061180084 |
|---|---|
| Public title | W10TR-PRO1 |
| Scientific title | Immunotherapy using WT1 peptide and a pertussis whole cell vaccine against recurrent prostate cancer: A phase I/II study. - W10TR-PRO1 |
| Primary sponsor | Kitajima Kiyoaki |
| Secondary sponsors | Udaka Keiko |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1-2 |
| Conditions | Castration resistant prostate cancer patients with or without previous chemotherapy |
| Interventions | 3.0 mg of WT1 peptide and 5x10^8 inactivated pertussis whole cell vaccine in 0.1 ml will be administered intradermally. The treatment interval is essentially every week. |
| Registration date | Mar 22, 2019 |
| Target size | 60 |
| Secondary IDs | UMIN000001821 |
| Registry page | jrct.niph.go.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: